With a macrotube dilution method, MICs and MBCs were determined for three aminothiazolyl cephalosporins, cefpirome (HR 810), ceftazidiine, and ceftotaxime, against Pseudomonas aeruginosa, enterococci, Staphylococcus epidermidis, and methicillin-resistant, -susceptible, and -tolerant strains of Staphylococcus aureus. Comparatively, cefpirome was the most active agent against all gram-positive cocci, including enterococci and methicillin-resistant S. aureus, and was as active as ceftazidime against P. aeruginosa. MBCs of cefpirome were within two dilutions of the MICs for 91% of P. aeruginosa and 90% of gram-positive cocci strains tested, except methicillin-resistant S. aureus, for which the MBCs were within three dilutions for 90% of strains.
Although numerous cephalosporins have been developed recently, there remain wide gaps in their in vitro activity and therapeutic efficacy. Most third-generation agents have expanded activity against aerobic gram-negative rods, including Pseudomonas aeruginosa (1, 2, 15) . However, resistance to and enterococcal superinfections associated with many of these agents have developed (3, 14) . With their structural alteration, these agents have less activity against Staphylococcus aureus and Staphylococcus epidermidis than the first-generation cephalosporins (2, 4, 8, 9) . In addition, the emergence and increasing frequency of methicillin-resistant S. aureus (MRSA) strains (7) have led to therapeutic dilemmas. Some of these strains appear to be susceptible to cephalosporins by the disk method but resistant by quantitative dilution testing (16) . Generally, the use of cephalosporins against MRSA and enterococci in humans has been discouraged because of inconsistent therapeutic results (4) (5) (6) (7) 16) . The clinical significance of tolerance in S. aureus strains has also led to diverse therapeutic approaches with more limited roles for the cephalosporins (12) .
Cefpirome (HR 810) is a new cefotaxime-like aminothiazolyl cephalosporin. It has been reported to have an expanded spectrum ofactivity which includes problem pathogens such as P. aeruginosa, enterococci, and staphylococci (1, 10, 11, 13) . These studies used various methods, including broth microtiter and agar dilution, to determine MICs, but do not report MBCs and therefore do not give information about tolerance (MBC:MIC, >32) or the bactericidal activity of these agents.
Consequently, we studied the inhibitory and bactericidal activity of cefpirome, ceftazadime, another new aminothiazolyl cephalosporin, and cefotaxime by a macrotube dilution method against these problem pathogens. allowed no visible growth. A 0.05-ml portion was carefully removed from each tube and subcultured onto a blood agar plate to determine the MBC (99.9% kill). All plates were incubated overnight, and colony counts were performed. Growth control cultures and broth and drug sterility tests were included in each run. In addition, S. aureus ATCC 25923, S. aureus RMA096, and P. aeruginosa ATCC 27853 were included as controls. The MICs of cefpirome, cefotaxime, and ceftazidime for S. aureus ATCC 25923 were 0.25 to 0.5, 1, and 8 ,.gIml, respectively; the MBCs were 1 to 8, 2, and 32 ,ugIml, respectively. For P. aeruginosa the MICs were 4 to 8, 8 to 16, and 2 ,ug/ml and the MBCs were 4 to 16, 32, and 2 p.g/ml of cefpirome, cefotaxime, and ceftazidime, respectively. S. aureus RMA096 was tested seven times to study the reproducibility of the results from the method. The MICs were within one dilution in all instances. MBCs were within one dilution in 19 of 22 tests, within three dilutions in two instances, and within five dilutions in one instance.
The activity of cefpirome, ceftazadime, and cefotaxime against the test strains is shown in Table 1 . In general, cefpirome was much more active than cefotaxime and ceftazadime against all gram-positive bacteria tested. All S. epidermidis, MSSA, and MRSA-T strains tested were highly susceptible (MIC for 90% of strains [90% MIC], <0.5 xg/Iml) to cefpirome. All MRSA strains and enterococci tested were inhibited (90% MIC, <8 jig/ml) by cefpirome, but nine MRSA strains and five enterococci had MBCs of 32 to 128 j,ug/ml. The addition of 5% NaCl to the medium increased MICs and MBCs of cefpirome against MRSA by one to two dilutions. The clinical and biological significance of this effect of salt is unclear. In general, ceftazadime had relatively poor activity against all gram-postive cocci tested. Cefotaxime had good activity against S. epidermidis, MSSA, and MSSA-T strains but poor activity against MRSA and enterococci. Cefpirome was more active than cefotaxime and comparable in activity to ceftazidime against P. aeruginosa. MBCs were within two dilutions of the MIC for cefpirome, indicating bactericidal activity, for 91% of P. aeruginosa and 90% of MSSA and S. epidermidis strains, including those previously found to be tolerant to a variety of antimicrobial agents.
Our results showed that cefpirome has good activity against P. aeruginosa and excellent activity against grampositive organisms. It was active against S. aureus, including MSSA, MSSA-T, and MRSA strains, S. epidermidis, and enterococci, but was less active against enterococci and MRSA than against MSSA isolates. Only one enterococcal (MIC, 16 ,uag/ml; MBC, 64 ,ug/ml) and one MRSA strain (MIC, 16 ,ug/ml; MBC, 128 p.g/ml) were relatively resistant to cefpirome. By comparison, these isolates are usually not susceptible to cephalosporins. This is in accord with the MIC determinations-reported by other investigators (1, 10, 13) . In addition, our results showed that cefpirome was bactericidal, with MBCs within two dilutions of the MICs for almost all isolates tested except MRSA. Although the bactericidal levels were usually higher than the inhibitory levels, 25% of enterococci and 10% of MRSA isolates were still susceptible (<8 ,ug/ml), and 50% of enterococci were in the moderately susceptible range (<16 ,ug/ml) (11) . Although the clinical significance of tolerance in S. aureus remains unclear, these isolates were more susceptible to cefpirome (MBC range, 0.25 to 2 ,ug/ml) than to cefotaxime (MBC range, 2 to 64 ,g/ml) or ceftazidime (MBC range, 8 to 16 ,ug/ml).
This in vitro activity has been correlated with in vivo activity in laboratory animals (13) . Klesel et al. (13) studied the comnparative activity of cefpirome in the prevention and treatment of localized and systemic infections in both mice and rats. Cefpirome was found to be superior to ceftazidime, cefotaxime, ceftriaxone, cefoperazone, and moxalactam, with a 50% effective dose of 0.8 to 6.3 pug/ml against experimental MSSA infections. They also found it to be This study was supported by a grant from Hoechst-Roussel Pharmaceuticals, Sommerville, N.J.
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